USANA Health Sciences Inc. - 10-K Summary (Fiscal Year Ended Dec 28, 2002)
Business Context and Reporting Period
This report covers the fiscal year ended December 28, 2002. USANA Health Sciences, Inc. develops, manufactures, and distributes nutritional, personal care, and weight management products via a network marketing system using independent "Associates" and direct sales to "Preferred Customers." The company operates in six geographic segments: United States, Canada, Australia-New Zealand, Hong Kong, Japan, and Taiwan (commenced operations in October 2002).
Key Financial Metrics
| Metric | 2002 | 2001 |
|---|---|---|
| Net Sales | $133.8 million | $114.3 million |
| Gross Profit | $100.4 million (75.0% margin) | $81.5 million (71.3% margin) |
| Net Earnings | $8.5 million | $2.2 million |
| Diluted EPS | $0.82 | $0.23 |
| Operating Cash Flow | $15.9 million | $10.0 million |
| Cash & Equivalents | $6.7 million | $2.5 million |
| Long-Term Debt | $2.6 million | $6.0 million |
| Working Capital | $1.2 million | $0.4 million |
Expense Ratios (2002): Associate incentives were 38.3% of net sales; Selling, General, and Administrative (SG&A) expenses were 26.4% of net sales.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17.1% ($19.5 million) driven by a 17.9% increase in active Associates, full-year operations in Japan, price increases in Australia-New Zealand and North America, and the launch of the Taiwan market.
- Profitability: Net earnings increased significantly (287% year-over-year) due to improved operating margins, higher sales volume, lower interest expense, and a favorable effective tax rate of 32.4%.
- Debt Reduction: Long-term debt decreased from $6.0 million to $2.6 million as the company utilized strong operating cash flows to pay down principal.
- Share Repurchases: The company spent $7.9 million to repurchase 1,054,300 shares of common stock during the fiscal year.
Guidance, Outlook, and Risks
- Outlook: Management expects gross profit to reach approximately 77% of net sales in 2003 due to procurement efficiencies. Associate incentives are expected to rise slightly to 39% of net sales. SG&A is expected to decrease as a percentage of sales but rise in absolute dollars due to new market expansion.
- Expansion Plans: Operations are planned for South Korea (Q3 2003) and Mexico (Q1 2004).
- Risks:
- Regulatory: Subject to FDA, FTC, and international regulations regarding dietary supplements and network marketing practices. Potential for new GMPs or advertising restrictions.
- Market Dependence: Heavy reliance on independent Associates for sales; high turnover rates are a risk.
- Currency: Significant exposure to foreign exchange fluctuations (47.6% of sales were international in 2002) with no hedging instruments in place for major currencies as of year-end.
- Key Personnel: Dependence on founder Dr. Myron W. Wentz, who owns 52.39% of the company and serves as CEO/Chairman.
Investor Verification Checklist
- Verify the sustainability of the 17.9% growth in active Associates and whether this trend can be maintained without significant increases in incentive costs.
- Confirm the status of regulatory approvals for planned expansions into South Korea and Mexico.
- Review the impact of the expected increase in the effective tax rate to 36% in 2003 on future net earnings.
- Assess the company's exposure to foreign currency fluctuations given the lack of hedging instruments for major international markets.
- Monitor the execution of the Enterprise Resource Planning (ERP) system implementation planned for 2003.